John P Fruehauf
Overview
Explore the profile of John P Fruehauf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lao C, Moon J, Ma V, Fruehauf J, Flaherty L, Bury M, et al.
Cancer
. 2024 Sep;
131(1):e35587.
PMID: 39342463
Background: Cell cycle inhibition is an established therapeutic approach for some cancers. A multicenter, single-arm, phase 2 trial (ClinicalTrials.gov identifier NCT00937937) of the cyclin-dependent kinase inhibitor SCH 727965 (NSC 747135;...
2.
Zhuang E, Uchio E, Lilly M, Zi X, Fruehauf J
Biomed Pharmacother
. 2021 Oct;
143:112226.
PMID: 34649352
We carried out a phase II study to investigate the activity of docetaxel plus lycopene in advanced castrate resistant adenocarcinoma of the prostate. Patients were chemotherapy and biological therapy naive....
3.
Parmakhtiar B, Burger R, Kim J, Fruehauf J
Mol Cancer Res
. 2019 May;
17(8):1675-1686.
PMID: 31088908
Ovarian cancer growth under hypoxic conditions results in hypoxia-inducible factor-1α (HIF1α) stabilization. HIF1α is an adverse prognostic factor that may contribute to worse outcomes via its capacity to bind to...
4.
Fruehauf J, El-Masry M, Osann K, Parmakhtiar B, Yamamoto M, Jakowatz J
Cancer Chemother Pharmacol
. 2018 Jun;
82(2):353-360.
PMID: 29943192
Purpose: This phase II study evaluated the safety and clinical activity of pazopanib, a potent and mutlitargeted tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFRs)-1, -2 and...
5.
Tortorici M, Cohen E, Pithavala Y, Garrett M, Ruiz-Garcia A, Kim S, et al.
Cancer Chemother Pharmacol
. 2014 Oct;
74(6):1279-89.
PMID: 25336084
Purpose: Axitinib, a potent and selective inhibitor of vascular endothelial growth factor receptors, showed antitumor activity as a single agent against several solid tumor types in Phase II and III...
6.
Eroglu Z, Fruehauf J
Cancer Chemother Pharmacol
. 2013 May;
72(1):263-7.
PMID: 23636451
Cisplatin-based chemotherapy is recommended for use as first-line treatment for patients with advanced transitional cell carcinoma of the bladder. Unfortunately, 30-50 % of patients are ineligible for cisplatin due to...
7.
Lindner D, Wu Y, Haney R, Jacobs B, Fruehauf J, Tuthill R, et al.
Matrix Biol
. 2012 Dec;
32(2):123-32.
PMID: 23202046
Background: Reversibility of aberrant methylation via pharmacological means is an attractive target for therapies through epigenetic reprogramming. To establish that pharmacologic reversal of methylation could result in functional inhibition of...
8.
Trapp V, Lee K, Donate F, Mazar A, Fruehauf J
Melanoma Res
. 2012 Jul;
19(6):350-60.
PMID: 22760066
Melanoma cells characteristically produce increased levels of reactive oxygen species (ROS) because of the metal-binding properties of melanin and loss of structural integrity of the melanosome. Agents that deplete gluthathione...
9.
Chase D, Sill M, Monk B, Chambers M, Darcy K, Han E, et al.
Gynecol Oncol
. 2012 Jun;
126(3):375-80.
PMID: 22683587
Objective: To explore feasibility of measuring tumor blood flow as marker for antiangiogenic activity using DCE-MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging) in women with recurrent EOC/PPC treated with bevacizumab. Methods:...
10.
Kim K, Sosman J, Fruehauf J, Linette G, Markovic S, Mcdermott D, et al.
J Clin Oncol
. 2011 Nov;
30(1):34-41.
PMID: 22124101
Purpose: Metastatic melanoma, a highly vascularized tumor with strong expression of vascular endothelial growth factor, has an overall poor prognosis. We conducted a placebo-controlled, double-blind phase II study of carboplatin...